Cargando…
Successful identification of predictive profiles for infection utilising systems‐level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma
OBJECTIVES: Patients with multiple myeloma (MM) are at increased risk for infection. Clinical assessment of infection risk is increasingly challenging in the era of immune‐based therapy. A pilot systems‐level immune analysis study to identify predictive markers for infection was conducted. METHODS:...
Autores principales: | Doerflinger, Marcel, Garnham, Alexandra L, Freytag, Saskia, Harrison, Simon J, Prince, H Miles, Quach, Hang, Slavin, Monica A, Pellegrini, Marc, Teh, Benjamin W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790592/ https://www.ncbi.nlm.nih.gov/pubmed/33437482 http://dx.doi.org/10.1002/cti2.1235 |
Ejemplares similares
-
A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma
por: Lee, Keun-Wook, et al.
Publicado: (2005) -
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
por: Lesokhin, Alexander M., et al.
Publicado: (2023) -
Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019) -
Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020) -
Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)